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ABSTRACT
Introduction: Patients discharged from Critical Care
suffer from excessive longer term morbidity and
mortality. Physical and mental health measures of
quality of life show a marked and immediate fall after
admission to Critical Care with some recovery over
time. However, physical function is still significantly
reduced at 6 months. The National Institute for Health
and Care Excellence clinical guideline on rehabilitation
after critical illness, identified the need for high-quality
randomised controlled trials to determine the most
effective rehabilitation strategy for critically ill patients
at risk of critical illness-associated physical morbidity.
In response to this, we will conduct a randomised
controlled trial, comparing physiotherapy aimed at
early and intensive patient mobilisation with routine
care. We hypothesise that this intervention will improve
physical outcomes and the mental health and
functional well-being of survivors of critical illness.
Methods and analysis: 308 adult patients who have
received more than 48 h of non-invasive or invasive
ventilation in Critical Care will be recruited to a patient-
randomised, parallel group, controlled trial, comparing
two intensities of physiotherapy. Participants will be
randomised to receive either standard or intensive
physiotherapy for the duration of their Critical Care
admission. Outcomes will be recorded on Critical Care
discharge, at 3 and 6 months following initial
recruitment to the study. The primary outcome
measure is physical health at 6 months, as measured
by the SF-36 Physical Component Summary.
Secondary outcomes include assessment of mental
health, activities of daily living, delirium and ventilator-
free days. We will also include a health economic
analysis.
Ethics and dissemination: The trial has ethical
approval from Newcastle and North Tyneside 2
Research Ethics Committee (11/NE/0206). There is a
Trial Oversight Committee including an independent
chair. The results of the study will be submitted for
publication in peer-reviewed journals and presented at
national and international scientific meetings.
Trial registration number: ISRCTN20436833.
INTRODUCTION
Background and rationale
Over 100 000 patients are admitted to Critical
Care Units in the UK every year. It has been
recognised for some time that patients dis-
charged from Critical Care suffer from exces-
sive longer term morbidity and mortality.1
Quality of life (QoL), in terms of both physical
and mental health, is significantly reduced fol-
lowing a prolonged admission to Critical Care.
In survivors, there is a slow and incomplete
recovery in QoL over the next 6–12 months.2
In 2009, the National Institute for Health
and Care Excellence (NICE) published guid-
ance for rehabilitation after critical illness.3
The guideline noted that there were no
Strengths and limitations of this study
▪ The strengths of the study include the relatively
large sample size and pretrial power calculation,
the inclusion of a range of general Critical Care
patients, the multicentre recruitment (although
limited to three centres in the north of England),
applicability to UK practice, delivery of rehabilita-
tion to the control group; which reflects current
UK practice, and prolonged (6 months)
follow-up.
▪ Limitations include the number of sites and the
lack of 7-day rehabilitation interventions. Also,
the study is blinded to patient participants, but is
not blinded to their healthcare providers.
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published randomised controlled trials examining how
effective early mobilisation therapy is at reducing the risk
of adult patients developing physical and non-physical
morbidity after hospital discharge. The authors recom-
mended more research to determine which therapeutic
strategies are the most clinical and cost effective at
reducing the prevalence and severity of critical
illness-associated physical morbidity, psychological morbid-
ity, and cognitive dysfunction.
Since 2009, there have been a small number of pub-
lished randomised controlled trials of mobilisation
therapy in Critical Care. In a study based in two Medical
Critical Care Units in North America, 104 patients who
were previously functionally independent were rando-
mised to receive either early mobilisation therapy or
standard care. Early mobilisation therapy was found to
be safe and well tolerated, and resulted in better func-
tional outcomes at hospital discharge, a shorter duration
of delirium, and more ventilator-free days compared
with standard care.4 A single-centre study in medical
and surgical Critical Care patients randomised patients
to receive either daily standard physiotherapy or daily
standard physiotherapy with an active training session
using a bedside cycle ergometer. They found that add-
itional exercise training enhanced recovery of functional
exercise capacity, self-perceived functional status, and
muscle force at hospital discharge.5 A single-centre ran-
domised controlled trial in Australia compared normal
physiotherapy (active exercises and progressive mobilisa-
tion, 6 days/week, until hospital discharge) to an inten-
sive physiotherapy programme started in Critical Care
and continued through the ward stay and after hospital
discharge.6 There were no significant differences in any
of the outcome measures at any stage of follow-up
although the rate of change over time from first assess-
ment was greater in the intervention group. Recent sys-
tematic reviews and meta-analyses identified the need
for further controlled trials of better quality and larger
sample size studies, including evaluation of type, dur-
ation, frequency and intensity of physical therapy.7–10
There is, therefore, some evidence that early physio-
therapy in this group of severely ill patients may improve
both the rate and magnitude of recovery from critical
illness. However, the evidence base is incomplete and, in
particular, the optimum intensity of physiotherapy is not
known. To address this, we will carry out a randomised
controlled trial of intensive versus routine physiotherapy
in the critically ill.
Objective
The objective of the study is to compare two different
intensities of early physiotherapy on the rate and magni-
tude of recovery from critical illness in a general Critical
Care population of adult patients.
Study design
We will conduct a multicentre patient randomised, parallel
group, controlled trial comparing two intensities of
physiotherapy on physical QoL. Adult, critically ill patients,
ventilated for more than 48 h, will be randomised to the
control or intervention group (figure 1). The control
group will receive usual physiotherapy, including a once-
daily functional retraining session (Monday to Friday).
The intervention group will receive a more intensive
physiotherapy programme, including at least one func-
tional retraining session per day (Monday to Friday) and
an individualised structured exercise programme.
METHODS
Eligibility criteria
Participants will be recruited from the Critical Care
(Intensive Care or High Dependency) Units of partici-
pating hospitals. Eligible patients will be medical or sur-
gical patients aged 18 years or older having received
48 h or more of invasive or non-invasive mechanical ven-
tilation. The exclusion criteria are as follows: patients
receiving end-of-life care; patients with acute brain or
spinal cord injury; patients admitted following brain or
spinal cord surgery; patients with multiple trauma if
mobilisation therapy is unlikely to be possible; patients
with burns; patients with rapidly progressive neuromus-
cular disease; patients enrolled in another clinical trial
without a co-enrolment agreement in place; patients pre-
viously enrolled in the Extra Physiotherapy in Critical
Care study. Patients who have suffered cardiac arrest may
be recruited if the clinical team believes that there is a
possibility of recovery.
Study intervention
Following randomisation into the trial, each participant
will undergo a daily morning sedation hold, with the
exception of those participants who have neuromuscular
blocking agents administered, where severe agitation is
already present despite sedation, or where participants’
ventilatory parameters are so high that a sedation hold
would be deemed detrimental to participant safety. The
sedation hold will consist of the interruption of all con-
tinuous intravenous sedation11 and assessment of the
patient using the Richmond Agitation-Sedation Scale
(RASS).12 Participants will be assessed continuously
during this period, and sedation re-started (if required)
to achieve a sedation level of ‘easily roused and coopera-
tive’ (RASS of −1, 0 or +1). If the sedation hold is suc-
cessful, the participant will be screened for safety prior
to the start of physiotherapy (figure 2). If the participant
fails the sedation hold, or a sedation hold is not appro-
priate, passive range of motion exercises will be per-
formed in all four limbs and the trunk, as deemed
appropriate. The assessment of sedation will be repeated
for both groups in the afternoon with a second adjust-
ment of sedation if needed. This will control for sed-
ation breaks in that both groups will, on average, have
had their sedation controlled in the same manner.
Following this, the participants will be screened for
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safety and undertake physiotherapy as appropriate for
the group to which they have been randomised.
The safety screen will be conducted by the treating
physiotherapist in conjunction with nursing and medical
staff, as necessary. Participants meeting any of the follow-
ing criteria will fail the safety screen: mean arterial
pressure (MAP) <65 mm Hg; heart rate <40 or
>130 bpm; respiratory rate <5 or >40 breaths/min;
marked ventilator asynchrony; oxygen saturation <88%
or, if known respiratory disease, a 10% decrease from
normal oxygen saturation; active gastrointestinal bleed-
ing; acute myocardial ischaemia; actively undergoing a
procedure; agitation requiring increased sedatives in the
last 30 min; insecure airway; other significant events
deemed inappropriate by the Critical Care team for the
start of active physiotherapy (specifics to be recorded).
Following a successful safety screen, an assessment for
wakefulness will be completed. The participant must be
able to obey at least three of the following commands:11
(1) opening eyes in response to voice; (2)using eyes to
follow investigator on request; (3)squeezing hand on
request and (4)protruding tongue on request. If the par-
ticipant can follow at least three of these commands and
has a RASS of −1, 0 or +1, they will be deemed as
having achieved ‘wakefulness’, and active physiotherapy
can start (figure 2).
Figure 1 Study design.
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The physiotherapy techniques used in this trial include
functional retraining (figure 3) and individually tailored
exercise programmes, based on a muscle-strengthening
algorithm (figure 4). During functional retraining, parti-
cipants will undergo physiotherapy at one of five levels of
activity, only moving onto the next level when they are
able to achieve the activity at the current level. During
the individually tailored exercise programmes, partici-
pants will progress from active-assisted exercises through
to resisted exercises, via the use of various therapy
adjuncts, that is, hand weights, exercise band, and com-
puter game-based exercise. The duration and content of
therapy sessions from both treatment groups will be
recorded daily.
The control group will receive the standard intensity
of physiotherapy which is normally given on participating
units. This will consist of no more than 30 min of active
exercise comprising: functional retraining (figure 3) and,
if time permits, an individually tailored exercise pro-
gramme, based on a muscle-strengthening algorithm
(figure 4). Physiotherapy will occur from Monday to
Friday as there is no physiotherapy service available rou-
tinely at weekends.
The intervention group will receive an augmented
programme with a target delivery of 90 min of active
exercise per day, again from Monday to Friday. The
physiotherapy sessions will consist of functional retrain-
ing (figure 3) and an individually tailored exercise pro-
gramme, based on a muscle-strengthening algorithm
(figure 4). The delivery of this treatment will be divided
into one or more sessions depending on: the individual
participant’s tolerance of the programme; the need for
other medical and nursing interventions; and the pro-
gression of the participant’s recovery.
During the physiotherapy sessions, participants will be
monitored closely, and if any of the following occur, the
session will be stopped: MAP <60 mm Hg; heart rate
<40 or >130 bpm; oxygen saturation <88% (or, if known
respiratory disease, a 10% decrease from normal
oxygen saturation); marked ventilator asynchrony;
participant distress; new arrhythmias; myocardial
ischaemia; concern for airway integrity; endotracheal
Figure 2 Trial intervention protocol.
4 Thomas K, et al. BMJ Open 2015;5:e008035. doi:10.1136/bmjopen-2015-008035
Open Access
group.bmj.com on November 24, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
tube removal; fall to knees; or any other significant
event where the participant is unable to continue
rehabilitation.
Apart from the difference in the intensity of physio-
therapy, both groups will have the usual rehabilitation
pathway in participating units.
Figure 3 Functional retraining flow chart.
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Following discharge from Critical Care, both groups
will receive the same, standard intensity of ward-based
physiotherapy, and continue with their rehabilitation
pathway. In line with NICE guidance, participants will
receive an exercise diary to continue independently on
discharge from hospital. Any patient readmitted to
Critical Care will receive standard physiotherapy care
during the second and any subsequent readmissions. All
readmissions will be recorded.
Outcomes
Primary outcome measure
The primary outcome measure is physical health as mea-
sured by the Short Form 36 Health Survey (SF-36)
Physical Component Summary (PCS) score at 6 months
after randomisation.
Secondary outcome measures
Mental health: the SF-36 Mental Component Summary
(MCS) score.
Exercise capacity: the 6 min walk test.13
Muscle power: hand grip and quadriceps muscle
strength using a dynamometer14 (see online supplemen-
tary appendix S1).
Physical functional ability: measured at Critical Care
discharge using the Modified Rivermead Mobility
Index.15
Activities of daily living (ADLs): ability to perform ADLs
will be assessed using the Functional Independence
Measure (FIM).16 The FIM and other questionnaires may
be completed via a telephone call, rather than in person,
at the 3-month and 6-month follow-up visits.
QoL: SF-36 and EQ-5D questionnaires will be adminis-
tered to assess participants’ QoL. Utility values will be
derived from the EQ-5D and from the SF-36 using the
algorithm provided by the SF-6D.17 These will be used as
the outcome measures in the economic analysis.
Outcome and location: survival status and place of
residence will be recorded at hospital discharge, and 3
and 6 months following randomisation.
Delirium: before beginning rehabilitation, participants
will be screened for delirium using the Confusion
Assessment Method for the Intensive Care Unit.18
Ventilator-free days: defined as the number of days
from randomisation (day 1) to day 28 on which a patient
breathed without mechanical ventilation (includes non-
invasive ventilation) if the period of unassisted breathing
lasted at least 48 consecutive hours. Continuous positive
airways pressure is considered to be unassisted breathing.
Health economic outcomes: utility scores will be gen-
erated using the SF-6D algorithm and the EQ-5D scores.
Patient costs for hospital visits will be assessed at
6 months, using the Patient Costs Questionnaire (see
online supplementary appendix S2).
Figure 4 Strengthening programme algorithm.
6 Thomas K, et al. BMJ Open 2015;5:e008035. doi:10.1136/bmjopen-2015-008035
Open Access
group.bmj.com on November 24, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
The time schedule of assessments of participants is
shown in table 1.
Sample size
The trial is powered to detect a difference of five points
on our primary outcome (the PCS score of the SF-36 at
6 months following recruitment) between the interven-
tion and control groups. In a previous study, we found
that mean PCS at 6 months after hospital discharge was
34 with a SD of 10.19 This SD is similar to that reported
at 6 months in 110 participants in the standard limb of
the PRaCTICal UK 20 follow-up study (SD 11.7), and in
a follow-up study of 252 critically ill patients in The
Netherlands (SD 11.2).21 Taking a SD of 11, a five-point
difference would give a medium effect size of 0.45. A
sample size calculation based on a power of 80% to
detect a five-point difference in SD at a significance level
of 0.05 would require 77 participants in each group, a
total of 154 for the trial. However, the 6-month mortality
in this group of patients is known to be approximately
40%. In addition, we anticipate that we may lose a
further 10% of participants to follow-up for other
reasons. We will therefore need to recruit a total of 308
participants (154 in each group).
Randomisation
Participants will be randomised in a 1:1 ratio, using per-
muted random block allocation, to either intervention
or control group. The randomisation process will be
administered centrally by Newcastle Clinical Trials Unit
via a secure web-based system. Randomisation will be
stratified by admitting Critical Care Unit, type of admis-
sion (surgical or medical) and the participant’s prehos-
pitalisation activity level. We will use Katz’s ADL Index22
to stratify participants into either ‘low’ activity (score of
0–3) or ‘high’ activity (score of 4–6).
Blinding
Owing to the nature of the intervention, it is not pos-
sible to blind the participants, clinical staff or research
staff to the treatment group. However, the outcome
assessments at hospital discharge, and at 3 and 6 months
after randomisation, will be undertaken by a research
nurse who will be blinded to the treatment group. To
avoid accidental unblinding, patients attending for
assessment will be requested not to reveal their treat-
ment group to the research nurse.
Data collection
The study data collected at each time point are
summarised in table 1. All participating units contribute
data to the Intensive Care National Audit and Research
Centre (ICNARC) case mix programme. Data collected
routinely by units as part of this national audit
will be used to provide demographic, diagnostic and
severity of illness data for participants. These data will
include: age; gender; admission diagnoses; Acute
Physiology and Chronic Health Evaluation (APACHE) II
severity of illness score; number of organ failures; admis-
sion and discharge location; length of stay (in Critical
Care and in hospital); status on hospital discharge; and
ultimate discharge location. An estimate of each partici-
pant’s premorbid functional ability (Katz’s ADL Index)
will be made by interview with their next of kin. For
each day a participant remains in Critical Care, we will
record the type and total dose of sedatives and the total
calorie intake received as enteral or parenteral nutrition.
Data related to each physiotherapy session will be
Table 1 Schedule of data collection and outcome assessments
Randomisation
Rehabilitation
sessions
Critical
Care
discharge
Hospital
discharge
3 Months
from
enrolment
6 Months
from
enrolment
Demographic and diagnostic data X
Severity of illness: APACHE II
score
X
Premorbid activity X
Sedation hold X
Safety screen X
Session duration X
Session milestones X
Adverse events X
Quality of life: SF-36 and EQ-5D X X X
Six-minute walk test X X X
Functional Independence Measure X X X X
Grip strength, both hands X X X X
Quad strength, both legs X X X X
Body mass index X X X X
Modified Rivermead Mobility Index X
Patient costs questionnaire X
APACHE, Acute Physiology and Chronic Health Evaluation; SF-36, Short Form 36 Health Survey.
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collected by the physiotherapist allocated to that session,
under the supervision of the research physiotherapist.
We will assess participants at discharge from Critical
Care against the Modified Rivermead Mobility Index. At
hospital discharge, 3 and 6 months after study enrol-
ment, patients will be invited to attend a follow-up
appointment where the study assessments will take
place. Where feasible, appointments will coincide with
routine clinical follow-up, to enhance the likelihood of
good compliance. Participants who do not attend their
appointment will be followed up by telephone.
Data management
To preserve confidentiality, all participants will be allo-
cated a unique study identifier, which will be used on all
case report forms and questionnaires. To allow for the
possibility that the incorrect unique study identifier is
recorded, the participant’s initials will also be recorded
on each case report form and questionnaire. Only a
limited number of members of the research team will be
able to link this identifier to patient-identifiable data,
which will be held on a password-protected data base. All
study documentation will be held in secure offices. Data
management will be undertaken using a Microsoft Access
database for data entry and processing, allowing a full
audit trail of any alterations made to the data postentry.
Original case report forms, questionnaires and consent
forms will be archived securely at The Newcastle upon
Tyne Hospitals NHS Foundation Trust’s archive facility
for 5 years following publication of the last paper or
report from the study. Data will be handled, compu-
terised and stored in accordance with the Data
Protection Act 1998. No patient-identifiable data will
leave the study sites. The quality and retention of study
data will be the responsibility of the Chief Investigator. All
study data will be retained in accordance with the latest
Directive on Good Clinical Practice (2005/28/EC).
Trial registration
In keeping with Good Clinical Practice, the study under-
went all ethical requirements and applications for regis-
tration prior to the start of recruitment to the study.
Application for registration of the trial via the National
Institute for Health Research Integrated Research
Application System was submitted on 30 June 2011, but
due to a delay in administration, the trial did not appear
on the registry until 20 February 2012, shortly after the
start of recruitment. At this particular time, a system
which automatically registered National Institute for
Health Research-funded studies via the IRAS system was
not in place. All legal ethical requirements were in place
prior to the start of recruitment.
ANALYSIS
Statistical analysis
The PCS component of the SF-36 at 6 months following
recruitment is the primary end point of the study. In
order to test the primary hypothesis of no difference
between the intervention and control groups, the princi-
pal analysis will examine the difference between the
groups on this measure using Analysis of Covariance
(ANCOVA) in order to adjust for the effects of covariates
in the analysis. The normality of the outcome variable
will be assessed and, if necessary, transformations consid-
ered although ANCOVA are robust to deviations from
this distribution. The covariates to be considered will
include stratification variables (unit, admission type and
preadmission activity level) in addition to demographic
variables such as age and gender. More basic illustrative
analyses using the t test or non-parametric alternatives
may also be undertaken while, in addition, summary sta-
tistics will be calculated.
A broadly similar approach will be used to analyse the
secondary outcome measures (the MCS component of
the SF-36, the 6 min walk test, FIM, grip strength, quad-
riceps strength and body mass index (BMI)) at both 3
and 6 months post-study entry, in addition to at hospital
discharge. Additionally, the 3-month and hospital dis-
charge data on the PCS component of the SF-36 will be
analysed in this fashion, along with the FIM, grip
strength and BMI outcomes at Critical Care discharge.
Repeated measures methods (again based on analysis of
variance) will be employed in order to examine these
outcome measures longitudinally across collected time
points. Standard survival data methods, such as
Kaplan-Meier and the log rank test, will be used to
compare survival between the groups at 3 and 6 months.
We will also compare durations of Critical Care and hos-
pital stay, in addition to the delirium and ventilator-free
days measures.
There are no planned interim analyses or stopping
rules. An allowance for loss to follow-up has been
included in the sample size calculation; data with missing
observations due to loss to follow-up, as opposed to mor-
tality, will be examined to determine both the extent of
missing data and whether data are missing at random or
are informative. If data are missing to a sufficient extent,
the use of appropriate imputation techniques will be con-
sidered to allow for this in the analysis. All analyses will
initially be performed on an intention-to-treat basis,
although it may be useful to consider additional per-
protocol analyses. We may base an analysis on groups
defined by a dichotomisation (into long or short) length
of stay in Critical Care, in addition to considering other
subgroup analyses. A statistical analysis plan will be
written and agreed by the Trial Oversight Committee
(TOC) before analysis of the study data.
Economic analysis
The economic analysis within this trial will consist of an
extensive cost analysis of both the control and interven-
tion groups from the NHS perspective, and will identify
the key items (if any) that underpin any significant cost
differences between the two trial groups. A societal per-
spective on costs will also be taken to include costs that
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fall on the patients, their carers/families and/or non-
NHS cost centres that result from the different treatment
regimes. Data will be gathered through the administra-
tion of the Participant Costs Questionnaire (see online
supplementary appendix S2), which was designed specif-
ically for this study, and may be the first of its type to be
published. This latter work will complement the main
NHS perspective of the cost analysis. In terms of effective-
ness, health-related QoL data based on the SF-36
collected at three time points in the trial’s follow-up will
be analysed using the SF-6D algorithm17 to produce
utility scores. Utility scores based on SF-36 will also be
compared against absolute utility scores derived from the
EQ-5D23 collected at the 6-month follow-up. Depending
on what the data show, and what realistic assumptions we
can make, we may proceed to a cost-utility analysis and
undertake extensive probabilistic sensitivity analysis.24
Trial management
Day-to-day running of the trial will be overseen by a
TMG, comprising, as a minimum, the Chief Investigator,
Senior Trial Manager, Trial Manager, Trial Statistician
and Data Manager. TMG meetings will take place on a
regular basis throughout the duration of the study. The
TMG will have responsibility for ensuring the compliance
and progress of the study in relation to all regulatory,
administrative academic and any clinical or safety issues.
Trial monitoring and oversight
Monitoring of study conduct and data collected will be
performed by a combination of central review and site
monitoring visits to ensure the study is conducted in
accordance with the International Conference on
Harmonisation Good Clinical Practice Guidelines. Study
site monitoring will be undertaken by the Newcastle
Clinical Trials Unit.
As agreed by the sponsor, a TOC will adopt the joint
roles of Trial Steering Committee (TSC) and Data
Monitoring and Ethics Committee (DMEC), with inde-
pendent members meeting in a closed session to fulfil
the DMEC role. The TOC will consist of the Chief
Investigator, an independent Chair/clinician, the Trial
Statistician, independent lay representative and the
TMG; a representative of the funder will be invited to
attend. The purpose of this committee will be to
monitor efficacy and safety end points, although only
independent members will have access to un-blinded
study data. A written charter will be agreed and used by
the TOC.
After 6 months of recruitment, initial rates of recruit-
ment will be used to project total recruitment, to ensure
sufficient participants to power the trial. The TOC will
advise on whether to continue or discontinue the study
and make a recommendation to the sponsor. The trial
may be prematurely discontinued on the basis of new
safety information, or for other reasons given by the
TOC, sponsor, regulatory authority or research ethics
committee. If the study is discontinued prematurely,
active participants will be informed, and no further par-
ticipant data will be collected.
Adverse event reporting
The participants recruited into this study are critically ill
with a high likelihood of significant morbidity and mor-
tality. Many will have life-threatening conditions, and we
expect that a large proportion of the participants will
experience Adverse Events (AE) and Significant Adverse
Events (SAE) during the time between randomisation
and discharge from Critical Care. For this reason, the
time period for AE and SAE reporting will begin with
each sedation hold (if performed), continue through
each physiotherapy session, and end 30 min after the
end of each physiotherapy session. All adverse events
occurring during the reporting period will be recorded
on an AE/SAE Report Form, and categorised as to the
degree of expectedness, relatedness and severity. All
SAEs that occur during the reporting period must be
reported to the Chief Investigator within 24 h of learn-
ing of the event, and a completed report form sent to
the Trial Manager. An SAE occurring to a research par-
ticipant should be reported to the main research ethics
committee where, in the opinion of the Principal
Investigator, the event was related to administration of
any of the research procedures and unexpected (ie, not
listed in the protocol as an expected occurrence).
A confirmed, related SAE will be reported to the
research ethics committee within 15 days of the Chief
Investigator becoming aware of the event. In addition,
the trial sponsor will be notified of the SAE.
There are a number of AEs that may be expected to
occur in patients undergoing physiotherapy in Critical
Care and do not need to be reported, these are: MAP
<65 mm Hg; HR<40 or >130 bpm; respiratory rate <5 or
>40 breaths/min; marked ventilator asynchrony; oxygen
saturation <88% or, if known respiratory disease, a 10%
decrease from normal oxygen saturation; marked venti-
lator asynchrony; patient distress; new cardiac arrhyth-
mia; myocardial ischaemia; insecure airway; fall to knees.
ETHICS AND DISSEMINATION
Consent
The consent process will depend on whether the patient
has capacity to give informed consent. Eligible patients
with capacity to consent will be approached by trained
members of the research team who will describe the
trial, including the potential risks and benefits, and
provide a participant information sheet. The patient will
be given time to consider whether they wish to take part
in the trial and to ask any questions. The member of the
research team will then invite the patient to sign the
consent form. If an eligible patient lacks capacity to
consent, a personal consultee will be approached in the
same way as for a patient with capacity. They will be
asked whether, in their opinion, the patient would agree
to take part in the trial, and will be invited to sign the
Thomas K, et al. BMJ Open 2015;5:e008035. doi:10.1136/bmjopen-2015-008035 9
Open Access
group.bmj.com on November 24, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
personal consultee declaration form. If, despite reason-
able efforts by the research team a personal consultee
is not available, a professional consultee will be
approached and given an information sheet. The profes-
sional consultee will be the consultant responsible for
the patient’s care before admission to Critical Care. In
determining what the person’s wishes and feelings about
the research would be if they had capacity, the nomi-
nated professional consultee should attempt to seek
views from any family, friends or carers who may not be
willing or able to act as a personal consultee. Where
appropriate, other professional colleagues with an inter-
est in the welfare or condition of the person who lacks
capacity, such as other members of the care team not
involved in the research, may be approached for a view.
If the professional consultee deems that the patient
would be willing to enter the study, they will be invited
to sign a professional consultee declaration form.
Retrospective consent
If a participant recovers from their illness and regains
capacity to give consent, the same consent procedure will
be carried out, as though the participant had capacity
before randomisation. In these cases, a retrospective
patient information sheet and consent form will be used.
Participants who lose the capacity to consent during the
trial period
The majority of critically ill patients will suffer from
periods of impaired consciousness where their capacity
to make informed decisions will be impaired or absent.
If a patient has consented to join the study, it will be
assumed that he or she would wish to continue in the
trial, even if the capacity to make an informed decision
is subsequently lost.
We anticipate a relatively short time window between
the time of patients meeting eligibility criteria and the
time that physiotherapy would be feasible. Because of the
need to give patients and personal consultees sufficient
time to consider participation in the trial, we will provide
information sheets for patients who are judged likely to
be eligible for the trial. Practically, this will include any
patient who is receiving mechanical non-invasive or inva-
sive ventilation, and in the opinion of the responsible
intensive care consultant is likely to be receiving mechan-
ical ventilation after 48 h. While this approach will allow
patients and personal consultees sufficient time to con-
sider participation in the trial, some may inevitably
receive information regarding a trial for which they (or
their family member) do not become eligible.
Withdrawal of consent
Participants will have the right to withdraw from the trial
at any time for any reason, or without giving a reason.
Participants no longer wishing to participate in the trial
may choose either to withdraw completely, or to with-
draw only from the study treatment, but continue to
provide follow-up data. Participants will be asked if the
data collected up to the point of withdrawal may be
retained, and if they are happy, for the reason for the
decision to withdraw to be recorded. Personal and pro-
fessional consultees also retain the right to withdraw
from the trial the participant whom they represent.
Dissemination
The results of the trial will be presented at national and
international meetings and published in peer-reviewed
journals. A lay summary of the results will be available to
trial participants on request. An online summary of the
findings, and implications of the trial, will be offered to
the intensive care patient support charity ICUsteps.
Trial status
The trial is currently in follow-up. The first patient was
recruited on 16 January 2012, and the final patient was
recruited on 4 December 2014.
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